Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

Bakrania, Anita and Zheng, Gang and Bhat, Mamatha (2021) Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics, 14 (1). p. 41. ISSN 1999-4923

[thumbnail of pharmaceutics-14-00041-v2.pdf] Text
pharmaceutics-14-00041-v2.pdf - Published Version

Download (948kB)

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of improving the safety and efficacy of treatment for HCC. Although remarkable success has been achieved in nanomedicine research, there are unique considerations such as molecular heterogeneity and concomitant liver dysfunction that complicate the translation of nanotheranostics in HCC. This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years.

Item Type: Article
Uncontrolled Keywords: hepatocellular carcinoma; liver cancer; nanoparticle; nanomedicine; gene therapy
Subjects: European Repository > Medical Science
Depositing User: Managing Editor
Date Deposited: 10 Nov 2022 05:15
Last Modified: 03 Jan 2024 06:14
URI: http://go7publish.com/id/eprint/114

Actions (login required)

View Item
View Item